Prescription drug prices fell 3.1% in the year through July, the largest annual decline in more than six decades, as the Trump administration expands direct-purchase discounts, international price benchmarking and Medicare drug-pricing initiatives.
By yourNEWS Media Newsroom
Prescription drug prices posted their largest annual decline since the early 1960s in July, providing an unusual source of consumer relief as broader medical costs and many other household expenses continue to rise.
Prices for prescription medicines fell 3.1% during the 12 months ending in July, according to new Bureau of Labor Statistics data.
That marked the steepest year-over-year decline since March 1963.
The broader category of medicinal drugs declined 2.7% over the same period.
The recent downward movement has been even more pronounced when measured over the first half of the year. Prescription drug prices fell at a 6.6% annualized rate during the six months through July, the largest six-month decline on record, according to the report.
The figures stand out because medical expenses overall have continued increasing, leaving prescription drugs as one of the comparatively few major categories in which consumers have experienced substantial price relief.
The White House pointed to the July numbers as evidence that President Donald Trump’s push to reduce prescription costs is beginning to show results.
Trump has made drug prices a central domestic policy issue, repeatedly arguing that Americans pay considerably more for many medicines than patients in other developed countries.
His administration has pursued several approaches simultaneously, including direct-to-consumer purchasing, international price comparisons, expanded Medicare negotiations and programs targeting some of the most expensive and widely used medications.
One of the administration’s most visible initiatives is TrumpRx, a direct-to-consumer platform intended to give patients access to certain prescription medicines at discounted prices while allowing them to compare available options.
The administration has also revived and expanded its push for so-called most-favored-nation pricing.
Under that approach, U.S. prices for certain drugs would be tied more closely to lower prices paid in comparable foreign markets.
Trump has argued that the existing system effectively requires American patients to subsidize lower prices offered in other countries and has pressed pharmaceutical manufacturers to narrow those differences.
The administration has placed particular emphasis on GLP-1 medications, a class of drugs that includes treatments widely used for weight loss and metabolic conditions.
Under the Medicare GLP-1 Bridge program launched in July, eligible Medicare beneficiaries can obtain certain medications at a net monthly price of $245, with a $50 copay.
The program includes Wegovy, Zepbound and Foundayo.
Those medications have drawn considerable attention because of both their popularity and their cost, making them a prominent part of the administration’s broader effort to demonstrate tangible savings for patients.
Medicare drug negotiations represent another major component of the federal pricing strategy, although that program predates the current Trump administration.
Congress created Medicare’s authority to negotiate the prices of certain high-cost prescription drugs through the Inflation Reduction Act in 2022.
The first negotiated prices took effect in 2026.
Those initial negotiations covered 10 drugs and were estimated to save Medicare approximately $6 billion while reducing beneficiaries’ out-of-pocket expenses by about $1.5 billion.
The Trump administration has continued the negotiation program rather than abandoning it and has moved to broaden its reach.
The Centers for Medicare and Medicaid Services has selected additional medicines for future negotiation rounds and proposed a permanent framework governing subsequent price-setting cycles.
That history complicates claims that the entire July decline can be attributed to policies created by Trump alone.
Some of the federal mechanisms currently affecting drug prices began under the previous administration, while others — including TrumpRx, most-favored-nation efforts and the GLP-1 initiative — are initiatives advanced or expanded under Trump.
The July data nevertheless arrive at a politically significant moment for the White House.
Trump has repeatedly made the price of prescription medicines a test case for his broader argument that the federal government should use its purchasing power and regulatory authority more aggressively when negotiating with pharmaceutical companies.
The latest figures give the administration a measurable result to point to: prescription drug prices are falling nationally at a pace not seen in more than 60 years.
The 3.1% annual decline is particularly notable because pharmaceutical pricing has historically moved upward rather than downward over long periods.
The six-month annualized decline of 6.6% suggests that much of the reduction has occurred relatively recently.
Whether that pace continues will depend on future pricing decisions by drugmakers, the implementation of federal programs and the mix of medications included in the government’s various discount and negotiation initiatives.
The administration is also seeking to make lower prices more visible directly to consumers rather than relying exclusively on savings negotiated within Medicare or other government programs.
That approach is central to TrumpRx, which is designed around the idea that patients should be able to see and access discounted prices more directly.
At the same time, most-favored-nation pricing represents a more confrontational strategy toward manufacturers.
Rather than focusing solely on negotiated discounts within the United States, the policy seeks to use prices charged abroad as a benchmark for what American consumers and government programs should pay.
Trump has argued that pharmaceutical companies should not charge U.S. patients substantially more for the same medicines sold at lower prices elsewhere.
The White House is therefore presenting the July inflation data as validation of a multipronged strategy rather than the product of any single policy.
The latest numbers do not by themselves establish exactly how much of the decline resulted from each individual government initiative, changes in manufacturer pricing, shifts toward generic drugs or other market forces.
They do, however, confirm that consumers experienced a substantial overall decline in prescription drug prices during the past year.
For an administration that has made medicine affordability a major political and economic issue, that provides a favorable benchmark.
Prescription prices fell 3.1% from a year earlier, medicinal drug prices declined 2.7%, and the six-month annualized decline reached 6.6% — figures that place the current downturn in drug costs at levels not recorded in decades.
The administration is now seeking to extend that trend through additional negotiations, international pricing pressure and programs aimed at reducing what Medicare beneficiaries and other patients pay directly at the pharmacy counter.
Original article
Comments